Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study

[1]  P. Ganly,et al.  Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  G. Morgan,et al.  Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US , 2021, Annals of Hematology.

[3]  N. Puig,et al.  Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma. , 2021, Future oncology.

[4]  H. Goldschmidt,et al.  Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  R. Hájek,et al.  Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice , 2020, BMC cancer.

[6]  M. Dimopoulos,et al.  Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma , 2020, Annals of Hematology.

[7]  S. Trestman,et al.  Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study , 2020, Annals of Hematology.

[8]  M. Dimopoulos,et al.  Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd , 2020, Expert review of hematology.

[9]  N. Puig,et al.  Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: Analysis of over 3,000 Pts from the Insight MM Global, Prospective, Observational Study , 2019, Blood.

[10]  A. Palumbo,et al.  Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma. , 2019, Clinical lymphoma, myeloma & leukemia.

[11]  M. Dimopoulos,et al.  A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial , 2019, Leukemia.

[12]  A. McBride,et al.  Special considerations for the treatment of multiple myeloma according to advanced age, comorbidities, frailty and organ dysfunction. , 2019, Critical reviews in oncology/hematology.

[13]  R. Vij,et al.  Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy , 2019, Leukemia.

[14]  Á. Illés,et al.  Real World Efficacy and Safety Results of Ixazomib Lenalidomide and Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program , 2019, Pathology & Oncology Research.

[15]  C. Cleeland,et al.  Patient‐reported health‐related quality of life from the phase III TOURMALINE‐MM1 study of ixazomib‐lenalidomide‐dexamethasone versus placebo‐lenalidomide‐dexamethasone in relapsed/refractory multiple myeloma , 2018, American journal of hematology.

[16]  P. Hari,et al.  The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed/refractory multiple myeloma in the era of novel therapies. , 2017, Journal of geriatric oncology.

[17]  Shankar Srinivasan,et al.  Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes , 2017, Clinical lymphoma, myeloma & leukemia.

[18]  A. Larocca,et al.  Elderly patients with multiple myeloma: towards a frailty approach? , 2017, Current opinion in oncology.

[19]  P. Richardson,et al.  Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1 , 2017, Haematologica.

[20]  D. Esseltine,et al.  Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma , 2017, British journal of haematology.

[21]  P. Moreau,et al.  Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials , 2017, Expert review of hematology.

[22]  K. Anderson.  Progress and Paradigms in Multiple Myeloma , 2016, Clinical Cancer Research.

[23]  A. Palumbo,et al.  Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. , 2016, The New England journal of medicine.

[24]  K. Ramasamy,et al.  Multiple myeloma in the very elderly patient: challenges and solutions , 2016, Clinical interventions in aging.

[25]  K. Anderson,et al.  Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. , 2015, Blood.

[26]  Hans Erik Johnsen,et al.  International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. , 2014, The Lancet. Oncology.

[27]  M. Epstein.  Guidelines for good pharmacoepidemiology practices (GPP) , 2005, Pharmacoepidemiology and drug safety.

[28]  Herbert Burkert,et al.  Some Preliminary Comments on the DIRECTIVE 95/46/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 24 October 1995 on the protection of individuals with regard to the processing of personal data and on the free movement of such data. , 1996 .

[29]  Christiane,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2013, JAMA.

[30]  Christiane,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2004, Journal international de bioethique = International journal of bioethics.